SHINE Medical Technologies said this week it has filled two newly established executive positions: chief strategy officer and general counsel.
As chief strategy officer for the medical isotope producer, Harsh Singh will work directly with SHINE CEO Greg Piefer. His duties will encompass fundraising, sales, marketing, investor relations, and corporate development, according to a company press release.
General Counsel Nathan Schleifer will report to President Todd Asmuth, providing oversight of legal, intellectual property, and compliance matters.
Singh most recently served since December 2016 as vice president, head of corporate development, for Hologic Inc., a medical technology provider headquartered in Marlborough, Mass., according to his LinkedIn profile. Prior to that, he spent nearly three years as a vice president at Mallinckrodt Pharmaceuticals in the Chicago area, focused on corporate strategy and mergers and acquisitions.
Singh “comes to SHINE with 18 years of experience structuring private capital financings, public offerings such as IPOs, and strategic transactions,” the press release says. “He has led strategy, business development, and general management positions at Fortune 500 companies in the nuclear medicine, medical device and pharmaceutical sectors.”
Schleifer started at SHINE in February, his LinkedIn profile says. Previously, he was associate general counsel for two years and nine months at YETI Coolers, assisting in the company’s 2018 initial public offering. He has also done stints in high-level counsel positions for Harley Davidson, W.W. Grainger, and API Healthcare.
Earlier this month, SHINE broke ground on its Janesville, Wis., production plant for the medical isotope molybdenum-99. The company has said it hopes to reach commercial output levels by 2021.
